NASDAQ:ABVC ABVC BioPharma (ABVC) Stock Price, News & Analysis → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free ABVC Stock Alerts $1.13 -0.12 (-9.60%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$1.05▼$1.2350-Day Range$0.99▼$1.5952-Week Range$0.67▼$9.60Volume980,321 shsAverage Volume1.67 million shsMarket Capitalization$11.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get ABVC BioPharma alerts: Email Address Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About ABVC BioPharma Stock (NASDAQ:ABVC)ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Read More ABVC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABVC Stock News HeadlinesApril 26, 2024 | finance.yahoo.comABVC BioPharma, Inc. (ABVC)April 26, 2024 | americanbankingnews.comShort Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Decreases By 59.6%May 2, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 18, 2024 | investing.comABVC BioPharma inks licensing deal for cancer drugApril 18, 2024 | finanznachrichten.deABVC BioPharma, Inc.: AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareApril 18, 2024 | globenewswire.comAiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareApril 17, 2024 | markets.businessinsider.comABVC BioPharma Enters Licensing Agreement With OncoX For Commercialization Of BLEX 404April 17, 2024 | finance.yahoo.comABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MMay 2, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 17, 2024 | globenewswire.comABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MApril 10, 2024 | globenewswire.comABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MMarch 28, 2024 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MMarch 27, 2024 | msn.comWhy ABVC BioPharma Stock Is Up TodayMarch 26, 2024 | markets.businessinsider.comABVC Announces Global Licensing Deal With ForSeeCon Eye For VitargusMarch 26, 2024 | globenewswire.comABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MMarch 21, 2024 | finance.yahoo.comAiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million DollarsMarch 19, 2024 | ca.finance.yahoo.comABVC BioPharma, Inc. (ABVC) Interactive Stock Chart - Yahoo FinanceMarch 19, 2024 | globenewswire.comABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia MagazineMarch 14, 2024 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateMarch 14, 2024 | globenewswire.comABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateFebruary 27, 2024 | finance.yahoo.comABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion DollarsFebruary 15, 2024 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 15, 2024 | markets.businessinsider.comABVC Signes Agreement To License Its 'Know-How' To SPIFebruary 15, 2024 | finance.yahoo.comABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 15, 2024 | globenewswire.comABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 12, 2024 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)February 12, 2024 | markets.businessinsider.comABVC BioPharma Receives Australian Patent For PDC-1421 For Treatment Of MDDSee More Headlines Receive ABVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today5/02/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABVC CUSIPN/A CIK1173313 Webwww.abvcpharma.com Phone(510)-668-0881FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,520,000.00 Net Margins-6,919.08% Pretax Margin-6,989.44% Return on Equity-226.65% Return on Assets-82.26% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.28 Sales & Book Value Annual Sales$150,000.00 Price / Sales79.55 Cash FlowN/A Price / Cash FlowN/A Book Value$1.02 per share Price / Book1.11Miscellaneous Outstanding Shares10,560,000Free Float9,303,000Market Cap$11.93 million OptionableNot Optionable Beta0.75 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Eugene Jiang (Age 38)Chairman & Chief Business Officer Comp: $200kDr. Uttam Yashwant Patil Ph.D. (Age 38)Chief Executive Officer Mr. Leeds Chow (Age 35)CFO & Principal Accounting Officer Comp: $180kDr. Tsung-Shann Jiang EMBA (Age 70)Ph.D., Chief Scientific Officer, Chief Strategy Officer & Director Comp: $200kKey CompetitorsAgeX TherapeuticsNYSE:AGEMIRA PharmaceuticalsNASDAQ:MIRAMonopar TherapeuticsNASDAQ:MNPRElevai LabsNASDAQ:ELABMoleculin BiotechNASDAQ:MBRXView All Competitors ABVC Stock Analysis - Frequently Asked Questions How have ABVC shares performed in 2024? ABVC BioPharma's stock was trading at $1.16 at the beginning of the year. Since then, ABVC stock has decreased by 2.6% and is now trading at $1.13. View the best growth stocks for 2024 here. Are investors shorting ABVC BioPharma? ABVC BioPharma saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 533,000 shares, a drop of 59.6% from the March 31st total of 1,320,000 shares. Based on an average daily volume of 946,600 shares, the days-to-cover ratio is currently 0.6 days. Approximately 6.1% of the shares of the company are short sold. View ABVC BioPharma's Short Interest. When is ABVC BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ABVC earnings forecast. How were ABVC BioPharma's earnings last quarter? ABVC BioPharma, Inc. (NASDAQ:ABVC) posted its quarterly earnings results on Wednesday, March, 13th. The company reported ($0.35) EPS for the quarter. ABVC BioPharma had a negative trailing twelve-month return on equity of 226.65% and a negative net margin of 6,919.08%. When did ABVC BioPharma's stock split? ABVC BioPharma's stock reverse split on Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did ABVC BioPharma IPO? ABVC BioPharma (ABVC) raised $7 million in an initial public offering (IPO) on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at a price of $6.25 per share. How do I buy shares of ABVC BioPharma? Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABVC) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
